A Weak Link: Chinese Courts Reluctant To Grant Preliminary Injunctions In Pharma IP Cases
This article was originally published in PharmAsia News
With a large number of pharma patents about to expire in China, hurdles to obtaining injunctive relief could be a huge problem, according to the EU Chamber of Commerce in China.
You may also be interested in...
Chinese Government Takes First Steps To De-link Indigenous Innovation And Procurement, But Industry Groups Wary
Insider Analysis From Morrison & Foerster LLP: China’s Bolar Exemption - Beware of the Uncertainties of Its Reach And Scope (Part 1 of 2)
Prices of direct acting hepatitis C drugs are down by 85% in China, with cancer and antidiabetes therapy costs cut by 65% and drug makers are rushing to celebrate. Scrip delves into the considerations behind the low prices and whether industry's excitement is a bit premature.